Despite remarkable advances in cancer treatment, gaps in the quality of care can lead to poor outcomes, especially among vulnerable populations. 1, 2 We all want to believe that when someone gets cancer they receive the highest quality of medical care; however, persistent problems in the health care system limit our ability to realize this goal. These deficiencies are caused, in part, by the inherent complexity of multidisciplinary cancer care, exposing patients to potential harm from fragmented care, access issues, and medical error. The Institute of Medicine report on cancer care in the United States describes a system in crisis, suffering from increasing demands in the face of limited resources and a lack of coordination. 3 Improving cancer care has been identified as a national priority, and establishing quality metrics has been prescribed as a requirement to chart a new course. There also is a growing interest in value-based reimbursement models tied to quality measures. Although not a panacea for health care, well-defined and well-implemented metrics provide an essential infrastructure on which to strengthen care delivery systems.
Challenges to measuring quality in cancer arise from the heterogeneous nature of cancer, complex multimodal treatment algorithms, prolonged continuum of care, and the large number of health care professionals involved in treating an individual cancer patient. Furthermore, "traditional" cancer outcomes such as survival and recurrence, although important, are limited in their ability to address salient quality metrics including safety, timeliness, efficiency, cost, or patient experience. Health care professionals involved in cancer patient care must be actively and meaningfully engaged in the improvement process in order for quality efforts to have any significant impact. The effectiveness of quality metrics to enhance clinical outcomes is largely tied to the relevance of the metrics selected, the degree to which they are "actionable," and the inherent quality of the data. Unfortunately, administrative/billing data sources commonly adapted for quality purposes often do not provide the level of detail or clinical relevance needed to inform care improvement. As illustrated in a survey of surgical oncologists, although most stated they were being monitored for quality, the majority felt that the measures were not adequate for patient care. 4 National efforts have been initiated to help address the quality gap in cancer care through the development of metrics for monitoring, benchmarking, and public reporting. [5] [6] [7] [8] These efforts hope to promote practice-based quality improvement, as it is only at this local level that meaningful transformations in cancer care can be achieved.
Quality metrics used to assess delivery of care can be broadly categorized into one of the 3 components originally defined by Donabedian: structure, process, and outcomes.
Structural measures reflect the physical properties or system characteristics in which care is delivered (eg, number of specialists, infusion center capacity). Structure measures are often necessary to provide good care, but usually are insufficient to ensure excellent quality. The best structure measures have a demonstrated influence on processes of care and patient outcomes. For example, reports have linked higher case volume to increased survival for a variety of cancer types and surgical oncology procedures. 9 This finding likely reflects a combination of structural and process factors present within high-volume facilities. This raises questions about whether to regionalize cancer care to high-volume centers versus developing strategies to replicate best practices at lower volume facilities. Structure measures tend to be very accessible, are commonly used for accreditation, but are not always actionable (eg, a cancer center may not be able to increase patient volume easily).
Process measures reflect appropriateness of interventions (eg, appropriate administration of adjuvant chemotherapy). In order for a process measure to be credible, there must be evidence linking the process to better outcomes. Studies have demonstrated that adherence to evidence-based guidelines in cancer care was associated with fewer treatment-related complications and greater longterm survival. 10 Interestingly, the research also suggested that adherence to guidelines could be facilitated through voluntary "peer pressure," and did not require financial rewards or penalties. One benefit of using process measures in cancer is that, unlike outcome measures, they typically are not subject to time lags (eg, monitoring breast cancer recurrence may require several years; however, monitoring the use of adjuvant breast radiation is an immediate process measure directly related to recurrence rates). Not surprisingly, the majority of quality measures in cancer have focused on process measures (eg, adherence to clinical guidelines). However, broader emphasis is needed on other process measures affecting patient experience, including use of patient navigation, shared decision making, and teamwork.
Outcome measures signify how the system directly affects the patient. They are helpful for benchmarking but can be affected by factors unrelated to the quality of treatment (eg, preexisting comorbidities). For this reason, cancer-specific risk adjustment models are essential. Outcomes are most useful when the process of care related to the outcome is known and the metric is relevant to the disease state (eg, if a chemotherapy agent is consistently able to shrink a particular tumor, but shrinkage of the tumor does not confer any clinical benefit, then it is not a useful outcome measure). In oncology, outcomes typically have consisted of various measures of survival. The need to place greater focus on patient-reported outcomes has been increasingly recognized. This includes patient satisfaction, symptom management, and functional status/quality of life following cancer treatment. Outcome measures should reflect the ability of the health system to meet patient expectations.
In addition to these 3 standard metrics, next-generation measures have been introduced including efficiency measures (eg, number of hospital visits from time of diagnosis to definitive treatment), balance measures that monitor unanticipated consequences of change interventions (eg, readmission rates observed during a pilot program to decrease length of stay), and cost measures (eg, total cost of treatment/financial burden on patient).
The interpretation of these quality metrics is facilitated by the use of dynamic displays of data (eg, run charts, control charts), which enable decision makers to appropriately assess the process and analyze the results of improvement initiatives. As espoused by Deming, reliance on summary statistics (eg, mean, median, mode, standard deviation) provides a limited understanding of the process being measured and may lead to conclusions not supported by a richer, dynamic display of data; specifically, differentiating between common cause variation (ie, inherent random variation present in all processes) and special cause variation (ie, unexpected events or unplanned situations resulting in outliers). Take, for example, measuring days from mammogram to diagnostic biopsy, or average appointment duration for chemotherapy. Displaying the data over time and applying defined probability-based rules/statistical process control can determine if the variation observed represents common versus special causes. If only common cause variation is present, any changes to improve the process should be holistic, system-based changes and not focused on particular "outliers," as there are none. Conversely, if special causes are present, efforts should be focused on either removing these outliers (if they are detrimental to the process) or replicating them (if they enhance the process).
Call to Leadership
Health care professionals in the "trenches" of patient care need to be actively engaged in quality efforts and must demonstrate proficiency using data for improvement. The real work of improvement (eg, narrowing unnecessary variation, addressing low performance, adhering to best practices, achieving culture change) must occur at the local level. Interprofessional collaborative teams, including cancer patients, should be formed around quality improvement efforts. Innovations in health information technology are required to assist these improvement efforts through automated data acquisition, interoperability of databases, point-of-care decision support, and realtime quality feedback. Adopting common standards of quality will help unite the efforts of various professional groups. Finally, quality improvement should address the demand for transparency and public reporting. Only then will the cumulative impact of these endeavors result in effective public health initiatives, successful cost control, and translation of best practices into better outcomes for patients with cancer.
